Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. (Q51024352)
Jump to navigation
Jump to search
scientific article published on 14 May 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. |
scientific article published on 14 May 2015 |
Statements
1 reference
Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. (English)
1 reference
Li Li
1 reference
Kapil Vashisht
1 reference
Julie Boisclair
1 reference
Wenkui Li
1 reference
Tsu-Han Lin
1 reference
Herbert A Schmid
1 reference
William Kluwe
1 reference
Heidi Schoenfeld
1 reference
Peter Hoffmann
1 reference
14 May 2015
1 reference
286
1 reference
224-233
1 reference
3
1 reference
Identifiers
1 reference